Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT® Fibrinogen Complex) is now FDA approved for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
Hemorrhage is a leading cause
of preventable death1
Hemorrhage increases mortality risk in trauma,2,3 cardiac surgery,4 and childbirth.5
Faster is better in
hemorrhage control
Every effort should be made to decrease the time to
administration of the first blood products.6
INTERCEPT® Fibrinogen Complex
The ready-to-use* pathogen reduced, fibrinogen enriched blood component is approved specifically for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.7
You May Also Be Interested In
WHAT'S IN THE BAG? When Minutes Matter. INTERCEPT Fibrinogen Complex is an enriched source of key constituents in effective hemostasis for the treatment and control of hemorrhage.
CLOT GENERATION: Successfully regaining hemostasis during hemorrhage requires a complex balance of factors involved in clot initiation and construction.
RESOURCES: View our resources area for package inserts and product information.
*INTERCEPT Fibrinogen Complex is available for immediate use for up to 5 days when stored thawed; when stored frozen, requires thawing prior to use.
References
1. Drake SA, Holcomb JB, Yang Y, et al. Establishing a Regional Trauma Preventable/Potentially Preventable Death Rate. Annals of Surgery 2018. 2. Stanworth SJ, Davenport R, Curry N, et al. Mortality from trauma haemorrhage and opportunities for improvement in transfusion practice. The British Journal of Surgery 2016;103:357-65. 3. Rourke C, Curry N, Khan S, et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. Journal of Thrombosis and Haemostasis : JTH 2012;10:1342-51. 4. Görlinger K, Shore-Lesserson L, Dirkmann D, Hanke AA, Rahe-Meyer N, Tanaka KA. Management of hemorrhage in cardiothoracic surgery. J Cardiothorac Vasc Anesth 2013;27:S20-34. 5. Butwick AJ, Goodnough LT. Transfusion and coagulation management in major obstetric hemorrhage. Current Opinion in Anaesthesiology 2015;28:275-84. 6. Meyer DE, Vincent LE, Fox EE, et al. Every minute counts: Time to delivery of initial massive transfusion cooler and its impact on mortality. The Journal of Trauma and Acute Care Surgery 2017;83:19-24. 7. INTERCEPT Blood System for Cryoprecipitation [Package Insert]; For the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex. Concord, CA: Cerus Corporation; January 20, 2021.
1. Drake SA, Holcomb JB, Yang Y, et al. Establishing a Regional Trauma Preventable/Potentially Preventable Death Rate. Annals of Surgery 2018. 2. Stanworth SJ, Davenport R, Curry N, et al. Mortality from trauma haemorrhage and opportunities for improvement in transfusion practice. The British Journal of Surgery 2016;103:357-65. 3. Rourke C, Curry N, Khan S, et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. Journal of Thrombosis and Haemostasis : JTH 2012;10:1342-51. 4. Görlinger K, Shore-Lesserson L, Dirkmann D, Hanke AA, Rahe-Meyer N, Tanaka KA. Management of hemorrhage in cardiothoracic surgery. J Cardiothorac Vasc Anesth 2013;27:S20-34. 5. Butwick AJ, Goodnough LT. Transfusion and coagulation management in major obstetric hemorrhage. Current Opinion in Anaesthesiology 2015;28:275-84. 6. Meyer DE, Vincent LE, Fox EE, et al. Every minute counts: Time to delivery of initial massive transfusion cooler and its impact on mortality. The Journal of Trauma and Acute Care Surgery 2017;83:19-24. 7. INTERCEPT Blood System for Cryoprecipitation [Package Insert]; For the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex. Concord, CA: Cerus Corporation; January 20, 2021.